Reimagine Medicine | Novartis

Media Release
Jun 09, 2023
Novartis unveils results from global patient and physician survey disrupting the notion that CML is a solved disease
Media Release
Jun 02, 2023
Novartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups
Media Release
Jun 01, 2023
Novartis receives European approval for Cosentyx® as first and only IL-17A inhibitor for hidradenitis suppurativa
Story
May 30, 2023
The future of medicine is here
Media Release
May 11, 2023
Novartis to feature new PNH and CML scientific data from broad hematology portfolio at European Hematology Association Annual Meeting
Media Release
Apr 26, 2023
Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa
Media Release
Apr 26, 2023
Novartis to present new data across oncology portfolio including Kisqali Phase III NATALEE trial in early breast cancer at ASCO
Media Release
Apr 26, 2023
Novartis Phase III APPOINT-PNH trial shows investigational oral monotherapy iptacopan improves hemoglobin to near-normal levels, leading to transfusion independence in all treatment-naïve PNH patients
Media Release
Apr 25, 2023
Novartis erzielt kräftige Umsatzsteigerungen, eine robuste Margenerhöhung und wichtige Innovationsmeilensteine. Erhöhung der Jahresprognose
Media Release
Apr 25, 2023
Novartis réalise une croissance forte de son chiffre d’affaires, une expansion robuste de sa marge, des étapes majeures de l’innovation et rehausse ses prévisions pour l’exercice 2023
Media Release
Apr 25, 2023
Novartis delivers strong sales growth, robust margin expansion and major innovation milestones. Raises FY guidance
Media Release
Apr 20, 2023
Novartis presents new five-year data on disability outcomes and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis